胶质母细胞瘤的分子和细胞基础的新见解。
Emerging insights into the molecular and cellular basis of glioblastoma.
机构信息
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
出版信息
Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112.
Abstract
Glioblastoma is both the most common and lethal primary malignant brain tumor. Extensive multiplatform genomic characterization has provided a higher-resolution picture of the molecular alterations underlying this disease. These studies provide the emerging view that "glioblastoma" represents several histologically similar yet molecularly heterogeneous diseases, which influences taxonomic classification systems, prognosis, and therapeutic decisions.
摘要
胶质母细胞瘤既是最常见的也是最致命的原发性恶性脑肿瘤。广泛的多平台基因组特征分析为这种疾病的分子改变提供了更清晰的图像。这些研究提供了一个新的观点，即“胶质母细胞瘤”代表了几种组织学上相似但分子上不同的疾病，这影响了分类学分类系统、预后和治疗决策。
相似文献
1
Emerging insights into the molecular and cellular basis of glioblastoma.
Genes Dev. 2012 Apr 15;26(8):756-84. doi: 10.1101/gad.187922.112.
2
Genomics illuminates a deadly brain cancer.
JAMA. 2010 Mar 10;303(10):925-7. doi: 10.1001/jama.2010.236.
3
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Radiographics. 2011 Oct;31(6):1717-40. doi: 10.1148/rg.316115512.
4
Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features.
Folia Neuropathol. 2012;50(4):301-21. doi: 10.5114/fn.2012.32361.
5
[Classification of glioblastoma and genome profiling].
Neurochirurgie. 2010 Dec;56(6):464-6. doi: 10.1016/j.neuchi.2010.07.009.
6
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.
Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9. doi: 10.1073/pnas.0402870102. Epub 2005 Apr 12.
7
Classification of glioblastoma multiforme in adults by molecular genetics.
Cancer J. 2003 Mar-Apr;9(2):82-90. doi: 10.1097/00130404-200303000-00003.
8
Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
Pathol Oncol Res. 2019 Jan;25(1):21-31. doi: 10.1007/s12253-017-0311-6. Epub 2017 Sep 26.
9
Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
Sci Rep. 2019 Jul 22;9(1):10555. doi: 10.1038/s41598-019-47066-y.
10
Genomics boosts brain-cancer work.
Nature. 2010 Jan 21;463(7279):278. doi: 10.1038/463278a.
引用本文的文献
1
High expression of SOX9 is a diagnostic and prognostic indicator of glioma.
Front Oncol. 2025 Jul 7;15:1531937. doi: 10.3389/fonc.2025.1531937. eCollection 2025.
2
CaMKK2 as a therapeutic target to combat metastasis in glioblastoma.
Mol Biol Rep. 2025 Jul 10;52(1):696. doi: 10.1007/s11033-025-10813-8.
3
Cancer/testis antigens FBXO39 and CEP55 expression correlates with survival in GBM patients.
PLoS One. 2025 Jun 12;20(6):e0326054. doi: 10.1371/journal.pone.0326054. eCollection 2025.
4
Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance.
Cells. 2025 Apr 9;14(8):562. doi: 10.3390/cells14080562.
5
Multi-transcriptomics reveals niche-specific expression programs and endothelial cells in glioblastoma.
J Transl Med. 2025 Apr 15;23(1):444. doi: 10.1186/s12967-025-06185-z.
6
The Co-Expression and Cellular Location of HER Family Members, EGFRvIII, Putative Cancer Stem Cell Biomarkers CD44 and CD109 in Patients with Glioblastoma, and Their Impacts on Prognosis.
Cancers (Basel). 2025 Apr 4;17(7):1221. doi: 10.3390/cancers17071221.
7
Inhibition of glioma cell viability by jatrophone via NF-κB down-regulation and apoptosis inhibitor up-regulation.
Arch Med Sci. 2020 Apr 15;21(1):224-232. doi: 10.5114/aoms.2020.94439. eCollection 2025.
8
Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.
J Neurooncol. 2025 May;172(3):527-548. doi: 10.1007/s11060-025-04989-z. Epub 2025 Mar 13.
9
Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.
Cancer Med. 2025 Mar;14(5):e70733. doi: 10.1002/cam4.70733.
10
Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model.
Brain Sci. 2025 Jan 31;15(2):146. doi: 10.3390/brainsci15020146.
本文引用的文献
1
Girdin maintains the stemness of glioblastoma stem cells.
Oncogene. 2017 Jun 29;36(26):3796. doi: 10.1038/onc.2017.17. Epub 2017 Feb 20.
2
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
3
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Nature. 2012 Feb 15;483(7390):484-8. doi: 10.1038/nature10898.
4
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866.
5
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3041-6. doi: 10.1073/pnas.1114033109. Epub 2012 Feb 8.
6
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
Nat Genet. 2012 Jan 29;44(3):251-3. doi: 10.1038/ng.1102.
7
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
Genes Dev. 2011 Dec 15;25(24):2594-609. doi: 10.1101/gad.176800.111.
8
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.
9
An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.
10
Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma.
J Exp Med. 2011 Dec 19;208(13):2657-73. doi: 10.1084/jem.20111102. Epub 2011 Dec 12.
Zotero 插件